STOCK TITAN

Amneal Pharmaceuticals, Inc. - $AMRX STOCK NEWS

Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: $AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a leading global pharmaceutical company headquartered in Bridgewater, NJ. Amneal develops, manufactures, and distributes a diverse portfolio of over 280 generic and specialty pharmaceutical products across the United States, India, and Ireland. With a commitment to providing affordable medicines, Amneal operates through three key segments: Generics, Specialty, and AvKARE.

Generics Segment: This segment focuses on producing a wide range of dosage forms and delivery systems, including injectables and biosimilars, contributing significantly to the company's revenue. The Generics segment is dedicated to expanding across complex product categories and therapeutic areas, ensuring patients have access to vital medications.

Specialty Segment: Amneal's Specialty segment promotes proprietary branded pharmaceuticals targeting central nervous system and endocrine disorders. The segment has a growing portfolio of branded pharmaceuticals with a pipeline focused on addressing unmet medical needs, demonstrating the company's commitment to innovation.

AvKARE Segment: This segment distributes pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution. AvKARE focuses on offering consistent care and pricing to qualified entities, enhancing access to essential medicines for governmental and institutional markets.

Recently, Amneal has achieved significant milestones, including the resubmission of a Complete Response to the FDA for IPX203, an oral formulation for Parkinson’s disease, and entering a licensing agreement with Zambon Biotech for IPX203 in Europe. The company also launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, underscoring their commitment to oncology treatment advancements.

Amneal's financial performance remains robust, with net revenue of $2.39 billion in 2023 and a strategic focus on expanding its reach through innovative products and international partnerships. The company continuously invests in research and development to meet the growing demands for affordable and high-quality medications, solidifying its position as a key player in the pharmaceutical industry. For more information, please visit www.amneal.com.

Rhea-AI Summary

Amneal Pharmaceuticals (Nasdaq: AMRX) announced the addition of six new injectable therapies in Q2 2024, expanding its US market portfolio to over 40 products. This move aims to address chronic shortages of critical injectables, especially in oncology. Notably, three of these new products are listed on the American Society of Health System Pharmacists (ASHP) drug shortage list, increasing Amneal's total ASHP-listed injectables to 13. The new products include PEMRYDI RTU® (vial), Atropine sulfate (pre-filled syringe), Docetaxel (injection), Foscarnet (IV bag), Methylprednisolone acetate (multi-dose vial), and Calcium gluconate (vial). The company has tripled its production capacity to 60 million units across four facilities and aims to introduce 60 injectables by 2025, including branded oncology products to enhance pharmacy efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
none
-
Rhea-AI Summary

Amneal Pharmaceuticals (Nasdaq: AMRX) has started supplying its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, 4mg, to U.S. retail pharmacies and the State of California. Approved by the FDA in April 2024, this generic equivalent to OTC NARCAN® HCI Nasal Spray is now available for direct distribution nationwide. The company has a distribution agreement with California under the CalRx® Naloxone Access Initiative and aims to produce approximately ten million two-packs annually at its New Jersey facility starting in 2025. Amneal is also engaging with other states and municipalities to expand access to this life-saving medication amid the ongoing opioid epidemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Summary

Amneal Pharmaceuticals (Nasdaq: AMRX) announced that its Co-CEO, Chirag Patel, and CFO, Tasos Konidaris, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024. Chirag Patel is scheduled to present at 1:30 PM EST. A live webcast of the presentation will be available on the company's website, with a replay accessible after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
Rhea-AI Summary

Amneal Pharmaceuticals, Inc. reported a Q1 2024 net revenue of $659 million, with a GAAP net loss of $92 million and diluted loss per share of $0.30. Adjusted EBITDA was $152 million with adjusted diluted EPS of $0.14. The company settled a nationwide opioids case and affirmed its 2024 full-year guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.86%
Tags
-
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) receives FDA approval for Over-the-Counter Naloxone Hydrochloride Nasal Spray, offering an affordable alternative to NARCAN®. The generic equivalent aims to combat opioid overdose emergencies, providing life-saving treatment without a prescription. Amneal's commitment to public health and accessibility drives the launch of this medication, important in the face of rising opioid-related fatalities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.04%
Tags
-
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. launches PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, catering to non-squamous non-small cell lung cancer and malignant pleural mesothelioma patients. The product eliminates the need for reconstitution, dilution, or refrigeration, enhancing pharmacy efficiency. Amneal plans to introduce two to three branded oncology 505(b)(2) products annually, with PEMRYDI RTU® being the first in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) will release its first quarter 2024 financial results on May 3, 2024, followed by a conference call and webcast. Investors can access the financial results and webcast through the Investor Relations section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences earnings
-
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) celebrates its listing on the Nasdaq Stock Exchange. Co-founders and Co-CEOs, Chirag and Chintu Patel, will ring the closing bell on April 2, 2024. The company emphasizes its growth as a global pharmaceutical leader with a diverse portfolio of essential medicines, focusing on patient access, affordability, innovation, and quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) receives FDA approval for ciprofloxacin and dexamethasone otic suspension, a new high-value product for treating ear infections. The product is indicated for Acute Otitis Externa in pediatric, adult, and elderly patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) reports Q4 2023 net revenue of $617 million, with a GAAP net loss of $99 million. Full-year 2023 net revenue reaches $2.39 billion. The company provides 2024 financial guidance of $2.55 to $2.65 billion in net revenue and $580 to $620 million in Adjusted EBITDA. The Co-CEOs highlight successful execution and growth, emphasizing the importance of providing high-quality, affordable medicines in a dynamic industry landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags

FAQ

What does Amneal Pharmaceuticals, Inc. specialize in?

Amneal Pharmaceuticals specializes in developing, manufacturing, and distributing a wide range of generic and specialty pharmaceutical products.

What are the key segments of Amneal Pharmaceuticals?

Amneal operates through three segments: Generics, Specialty, and AvKARE. The Generics segment focuses on a broad range of dosage forms and delivery systems, Specialty targets central nervous system and endocrine disorders, and AvKARE distributes pharmaceuticals to governmental agencies.

Where is Amneal Pharmaceuticals headquartered?

Amneal Pharmaceuticals is headquartered in Bridgewater, NJ, USA.

What recent product has Amneal Pharmaceuticals launched in the oncology space?

Amneal recently launched PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, catering to oncology treatments.

What is the significance of Amneal's IPX203?

IPX203 is a novel oral formulation for the treatment of Parkinson’s disease. Amneal has resubmitted a Complete Response to the FDA and entered a licensing agreement with Zambon Biotech for its commercialization in Europe.

How does Amneal Pharmaceuticals contribute to the U.S. pharmaceutical market?

Amneal contributes by addressing chronic market shortages, particularly in the injectables category, and providing high-quality, affordable medicines through its expanded manufacturing capabilities.

What financial performance did Amneal achieve in 2023?

In 2023, Amneal reported a net revenue of $2.39 billion and continues to show robust financial health and growth prospects.

How is Amneal addressing the opioid crisis?

Amneal launched an Over the Counter Naloxone Hydrochloride Nasal Spray to help treat opioid overdoses, significantly expanding access to life-saving medication.

What are some key partnerships of Amneal Pharmaceuticals?

Amneal has partnered with Zambon Biotech for the commercialization of IPX203 in Europe and has also entered a distribution agreement with California for the supply of Naloxone HCI Nasal Spray.

How can investors get more information about Amneal Pharmaceuticals?

Investors can visit Amneal’s official website at www.amneal.com for detailed information and latest updates.

Amneal Pharmaceuticals, Inc.

Nasdaq:AMRX

AMRX Rankings

AMRX Stock Data

2.13B
123.43M
59.78%
29.02%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Bridgewater